ALXN: Stock Quote & Summary Data |
Company Description (as filed with the SEC)
Alexion is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Our marketed product Soliris® (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. We are also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism, and we are progressing with other biotechnology product candidates in ultra-rare and severe disorders which are now in various stages of development. ... More ...
Links to all Alexion Pharmaceuticals, Inc. (ALXN) Pages
Stock Analysis
Fundamentals
Holdings
/Ownership
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $0.67 |
| Quarterly EPS Est: | 0.3 |
| PEG Ratio: | 2.08 |
| Mean Recommendation: View Summary/View All |
1.52 |
Data is provided by Zacks Investment Research
Home
Search NASDAQ
Search Web

Symbol List Views
Stock Details
CHARTS
COMPANY NEWS
STOCK ANALYSIS
FUNDAMENTALS
HOLDINGS
